PGEN Jul 2024 1.000 call
| Previous close | 0.7000 |
| Open | 0.6700 |
| Bid | 0.5000 |
| Ask | 0.8500 |
| Strike | 1.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.6700 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 160 |
Simply Wall St.Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
Precigen, Inc. ( NASDAQ:PGEN ) shareholders should be happy to see the share price up 15% in the last week. But only...
PR NewswirePrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released positive Phase 1/2 pivotal study results for the investigational PRGN-2012 off-the-shelf (OTS) AdenoVerse® gene therapy in patients with recurrent respiratory papillomatosis (RRP). Results were presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Scott
PR NewswirePrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast w
